Evidence map›Paper›PMID 39313453›Full record

ArticleYonsei medical journal2024

A Case Report of Lenacapavir Use in a Patient with Multidrug-Resistant HIV: The First Experience in Asia.

Yongseop Lee, Ki Hyun Lee, Jung Ah Lee, Sang Min Ahn, Min Han, Jun Yong Choi

Abstract readCase Reports
In one paragraph

Article in Yonsei medical journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yongseop LeeDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-0116-6710
Ki Hyun LeeDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-3138-6685
Jung Ah LeeDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0001-9891-5134
Sang Min AhnDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0003-0641-4493
Min HanDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0009-0003-1763-5643
Jun Yong ChoiDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.ORCID https://orcid.org/0000-0002-2775-3315

Funding

Korea Disease Control and Prevention Agency 2019-ER5101-00Korea Disease Control and Prevention Agency 2022-E1901-00Korea Disease Control and Prevention Agency 2022-ER1907-00
6 · The paper itself

Abstract

Lenacapavir is a novel, first-in-class, capsid inhibitor, which has been approved as an adjunctive therapy for multidrug-resistant human immunodeficiency virus (HIV)-1 virus in combination with optimized background regimen (OBR). Lenacapavir has demonstrated a significant decrease in viral load and high rate of virologic suppression in patients with multidrug-resistant HIV-1 infection with limited treatment options. Here, we report a case of 43-year-old male who was diagnosed with HIV-1 infection in 2005 but failed to achieve viral suppression due to multiclass resistance. After lenacapavir use with OBR, viral suppression was achieved, and recovery of CD4

Indexed as

Anti-HIV AgentsDrug Resistance, Multiple, ViralHIV-1HIV InfectionsViral LoadAdultAsiaCD4 Lymphocyte CountHumansMaleAnti-HIV Agentsacquired immunodeficiency syndromeanti-retroviral agentsdrug resistanceHIV

Identifiers

PMID39313453
PMCPMC11427126

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.